Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Articles > Article · 2016
Authors: A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, T Silovski, Erhan GÖKMEN, Minckwitz von, B Ejlertsen, SK Chia, J Mansi, CH Barrios, M Gnant, M Buyse, I Gore, J Smith, G Harker, N Masuda, K Petrakova, AG Zotano, N Iannotti, G Rodriguez, P Tassone, A Wong, R Bryce, Y Ye, B Yao, M Martin, Study ExteNET
The Lancet Oncology, Journal Indexed in SCI Expanded, International, WoS, 2016, vol 17, pp 367-377